Stock AnalizCronos Group Inc. CRON
Medicinal Chemicals and Botanical Products · data as of November 13, 2026
Cronos Group Inc. (CRON) is a healthcare company listed in the US with a market value of about $1.2B. In the twelve months to September 30, 2026 it had revenue of $206M and net income of $58M, a net margin of 28.0%.
Its overall Stock Analiz score is 3.2 out of 5 (average). The strongest part is value (4/5); the weakest is track record (1/5).
Key numbers: a P/E of 22.1, a price to free cash flow of 19.0, 5-year revenue growth of 26% a year, a 5-year average ROIC of -9%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 99% above the current price.
Score: 3.2 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
Checks not passed
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- ROE above 15%
- Interest covered more than 5 times
- Share count down over 3 years (buybacks)
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $206M | $147M | $118M | $87M | $87M | $65M | $47M | — | $12M | $3M | $411590 |
| Net income | $58M | -$9M | $41M | -$74M | -$169M | -$396M | -$73M | $1.2B | -$22M | -$1M | -$884101 |
| Free cash flow | $65M | $149000 | $6M | -$45M | -$92M | -$165M | -$176M | -$170M | -$96M | -$37M | -$6M |
| EPS (diluted) | $0.15 | $-0.03 | $0.11 | $-0.20 | $-0.46 | $-1.08 | $-0.20 | $3.18 | $-0.06 | $-0.00 | $-0.00 |
| Net margin | 28.0% | -6.4% | 34.9% | -84.8% | -194.5% | -613.5% | -156.5% | — | -178.5% | -45.6% | -214.8% |
| ROIC | — | -1.2% | -5.7% | -7.4% | -7.7% | -21.6% | -10.1% | -8.7% | -13.7% | -6.1% | -4.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 1 analysts is $2.96, 12% below the current price; targets range from $2.96 to $2.96; the consensus rating is “Strong buy”; expected EPS is $0.26 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Cronos Group’s P/E ratio?
About 22.1, based on the last twelve months of diluted earnings per share (forward P/E about 13.2).
Is Cronos Group stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 99% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Cronos Group pay a dividend?
Not currently.
Is Cronos Group a good stock to buy?
We do not give buy or sell advice. Cronos Group scores 3.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.